EUVIMEDEUVIMED entdecken
Open Access

Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival

Alexandra Berger, Sarah J Colpitts, Morgan Zych, Christopher J Paige

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03442-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Alexandra Berger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada. aberger@uhnres.utoronto.ca. Hauptthemen laut MEDLINE: Leukemia, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Leukemia and Lymphoma Society of Canada, Princess Margaret Cancer Centre Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have explored the use of an IL-21 cell-based anti-leukemia treatment in a mouse model of acute lymphoblastic leukemia. 70Z/3 leukemia cells, engineered to secrete IL-21 and injected into the peritoneum of syngeneic mice, induced a strong anti-leukemia response resulting in 100% survival. Mice that mounted an IL-21-induced anti-leukemia immune response were immune to the parent cell line (no IL-21) when rechallenged.Above a certain threshold, IL-21 secretion correlated with improved survival compared to mice injected with parent 70Z/3 cells. IL-21 was detected in serum with peak levels on day 7, correlating with the maximum expansion of IL-21-secreting 70Z/3 cells which subsequently were eliminated. Mice injected with IL-21-secreting leukemia cells had elevated numbers of granzyme B+ CD4+ and CD8+ T cells in the peritoneum, compared to mice injected with the parent cell line. Regulatory T cells, which increased greatly in 70Z/3-injected mice, failed to do so in mice injected with IL-21-secreting cells. Upon rechallenge, IL-21-primed mice went through a secondary immune response, primarily requiring CD4+ T cells, triggering a significant increase of CD4+CD44+CD62L- effector memory T cells. Adoptive transfer of T cells from IL21-primed/rechallenged hosts into naïve mice was successful, indicating that IL-21-primed antigen-experienced T cells convey immunity to naïve mice.Our study shows that delivery of IL-21 in a cell-based anti-leukemia protocol has the potential to induce a potent immune response leading to cancer elimination and long-term immunity-properties which make IL-21 an attractive candidate for cancer immunotherapy. Protecting against tumor antigens as well as improving cancer immunity is justified, as current strategies are limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeukemiaNeoplasmsMiceAnimalsT-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesGranzymesCD4-Positive T-LymphocytesMice, Inbred C57BLInterleukin-21

Stichwörter der Autor:innen

Cancer immunotherapyInterleukin-21LeukemiaRegulatory T cellsT cells

Substanzen

Interleukin-21Granzymes

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada. aberger@uhnres.utoronto.ca.
  • Princess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada.
  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, Canada.

Förderung

  • Leukemia and Lymphoma Society of Canada
  • Princess Margaret Cancer Centre Foundation

Zitieren

APA

Berger, A., Colpitts, S. J., Zych, M., & Paige, C. J. (2023). Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03442-2

Vancouver

Berger A, Colpitts SJ, Zych M, Paige CJ. Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03442-2

BibTeX
@article{Berger2023,
  author = {Berger, Alexandra and Colpitts, Sarah J and Zych, Morgan and Paige, Christopher J},
  title = {Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03442-2}
}
Kostenlos starten →